Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H4 | Q96RI1 | 20/20 | 0.87 |
| ▸ | ESR1 | P03372 | 1/20 | 0.87 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.87 |
| ▸ | PGR | P06401 | 1/20 | 0.87 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.87 |
| ▸ | AR | P10275 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18347328 | 0.95 | NR1H4 (0.79) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL18347329 | 0.93 | NR1H4 (0.76) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL4522612 | 0.93 | NR1H4 (0.87) | NR1H4ESR1NR3C1PGRNR3C2 | |
| Turofexorate Isopropyl SCHEMBL274657 | 0.93 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 | |
| Turofexorate Isopropyl SCHEMBL29382704 | 0.93 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 | |
| Turofexorate Isopropyl SCHEMBL29823687 | 0.93 | NR1H4 (1.00) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL18347324 | 0.92 | NR1H4 (0.75) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL18347343 | 0.92 | NR1H4 (0.73) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL18347338 | 0.91 | NR1H4 (0.73) | NR1H4ESR1NR3C1PGRNR3C2 | |
| SCHEMBL13756325 | 0.91 | NR1H4 (0.72) | NR1H4ESR1NR3C1PGRNR3C2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | claimed |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2018-06-21 | — | — | US | disclosed |
| US-9895380-B2 | Methods and pharmaceutical compositions for the treatment of hepatitis B virus infection | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2018-02-20 | — | — | US | disclosed |
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2018-01-04 | — | — | US | disclosed |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) | 2016-12-29 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | EXELIXIS, INC. (US) | 2009-08-13 | — | — | US | disclosed |
| WO-2007070796-A1 | AZEPINOINDOLE DERIVATIVES AS PHARMACEUTICAL AGENTS | EXELIXIS, INC. (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180000768-A1 | INTESTINAL FXR AGONISM ENHANCES GLP-1 SIGNALING TO RESTORE PANCREATIC BETA CELL FUNCTIONS | GLP1R, GIPR, FXR1 | NR1H4 10/4885ESR1 1524/4885NR3C1 382/4885 |
| US-20180169115-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF HEPATITIS B VIRUS INFECTION | NR1H4, FXR2, FXR1 | NR1H4 1/4885ESR1 1495/4885NR3C1 219/4885 |
| US-20160376279-A1 | FXR AGONISTS AND METHODS FOR MAKING AND USING | NR1H4, FXR2, FXR1 | NR1H4 1/4885ESR1 658/4885NR3C1 122/4885 |
| US-20090203577-A1 | Azepinoindole Derivatives As Pharmaceutical Agents | NR1H4, NR1I2, GPBAR1 | NR1H4 1/4885ESR1 292/4885NR3C1 231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.